Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the diagnosed prostate cancer market will experience dramatic growth, due to a rapidly aging population. According to the new Emerging Markets report entitled Prostate Cancer in China, the diagnosed prostate cancer population will grow 238% between 2006 and 2016. A rapidly aging population will be the key driver of this dramatic growth, but increases in life expectancy and significant rural to urban migration are exposing more men to prostate cancer risk factors.

The report also finds that the anticipated inclusion of Sanofi-Aventis's Taxotere for the treatment of prostate cancer in the next version of the National Reimbursement Drug List (NRDL) will expand the market for this chemotherapy agent by 36% per year. Traditionally, clinicians have refrained from using Taxotere, despite the fact that it has shown better efficacy than other chemotherapy agents for hormone-refractory prostate cancer, because of the high cost of treatment. Taxotere's inclusion on the NRDL will drive substantial growth during the forecasted period.

"Taxotere has become the chemotherapy agent most often prescribed in China for hormone-refractory prostate cancer," said Victor Li, Ph.D., analyst at Decision Resources. "Because physicians have observed a better response rate and longer survival with Taxotere than with other chemotherapy agents, they are treating more late-stage patients with chemotherapy than they have in the past."

About Emerging Markets - China

Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can:

  * More accurately assess their commercial opportunity for Western brands     in key pharmaceutical markets of China - Beijing, Shanghai, Guangzhou -     and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing,     Hangzhou, and Jinan.   * Understand the physician treatment patterns and drivers of choice in key     first- and second-tier cities based on primary research.   * Gain a clear perspective of the Chinese 5-year market forecast at the     drug level, broken out by urban and rural areas, and by sales from     multinational and Chinese-based companies.    About Decision Resources 

Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Fibromyalgia Drug Market Will Nearly Quadruple to $2 Billion by 2016

View Now